ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2679

Predictors of Fracture in SLE: A Longitudinal Cohort Study
Abstract Number: 0332

Predictors of Long-term Radiographic Changes in Patients with Idiopathic Inflammatory Myopathies Using Quantitative Imaging Analysis: Real World Experience from a Single Center Longitudinal Cohort
Abstract Number: 2163

Predictors of Patient Engagement and Usability in a Chronic Musculoskeletal Pain Management App
Abstract Number: 1004

Predictors of Post-acute Sequelae of COVID-19 in Patients with Rheumatoid Arthritis: A Retrospective Analysis of a Large Health System in the Midwestern United States
Abstract Number: 1759

Predictors of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis Receiving IL-17A Inhibitor or TNF Inhibitor Therapy over 2 Years: A Post Hoc Analysis of a Phase IIIb Study
Abstract Number: 0691

Predictors of Response and Long-term Efficacy and Safety of Nintedanib in Systemic Sclerosis-Interstitial Lung Disease: Data from an Italian Multicentre Study
Abstract Number: 0333

Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease
Abstract Number: 2325

Predictors of Treatment Response and Continuation in Patients with Psoriatic Arthritis Initiating Secukinumab – Results from the EuroSpA Collaboration
Abstract Number: 2322

Predictors of Work Impairment and Absence Amongst People with Psoriatic Arthritis (PsA) – Evidence from the British Society for Rheumatology PsA Register (BSR-PsA)
Abstract Number: 1487

Pregnancy Outcome and Risk Factors Analysis in Patients with Systemic Lupus Erythematosus Complicated with Thrombocytopenia
Abstract Number: 0440

Pregnancy Outcome Disparities Among Women with Systemic Lupus Erythematosus
Abstract Number: 0447

Pregnancy Outcomes in Women Exposed to Guselkumab: Review of Cases Reported to the Manufacturer’s Global Safety Database
Abstract Number: 0434

Pregnancy Outcomes of Biosimilars and Non-TNF Inhibitor Biologic Disease-Modifying Antirheumatic Drugs: A Scoping Review
Abstract Number: 2439

Preliminary Analysis of Open-Label Dose-Titration Phase of SLE Treatment with N-Acetylcysteine (SNAC) Shows Evidence for Potential Improvement of SLEDAI, BILAG, ADHD and Fatigue Scores in Patients with Active SLE
Abstract Number: 1666

Preliminary Effects of a Fully-Remote Online Physical Activity Program Following Knee Replacement

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].